SNOA

+ Watchlist + Portfolio

Sonoma Pharmaceuticals, Inc.

Regulated industry Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.25
52-Week Range: $0.85 – $4.60
Market Cap: $5.94M
P/E (TTM): —
EPS (TTM): -1.22
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.72
PEG Ratio: 1.08
Return on Equity: -42.52%
Return on Assets: -5.37%
Gross Margin: 38.90%
Operating Margin: -0.62%
Profit Margin: -10.33%
Current Ratio: 2.99
Debt/Equity: 0.11
Total Debt: $739.00K
Free Cash Flow: $-1.47M
Revenue Growth: 59.60%
Earnings Growth: —
Enterprise Value: $1.34M

SNOA Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$13.27M	$12.73M	$14.29M	$19.53M
Cost of Revenue	$8.79M	$7.99M	$8.82M	$12.11M
Gross Profit	$4.48M	$4.75M	$5.46M	$7.42M
Research & Development	$207.00K	$1.87M	$1.81M	$2.27M
Selling, General & Admin	$8.84M	$7.58M	$7.36M	$7.61M
Operating Expenses	$9.05M	$9.45M	$9.18M	$9.88M
Operating Income	-$4.57M	-$4.70M	-$3.71M	-$2.46M
EBITDA	-$4.45M	-$4.53M	-$3.57M	-$2.32M
Pretax Income	-$5.18M	-$5.03M	-$2.91M	-$3.42M
Income Tax	-$33.00K	-$196.00K	$550.00K	-$244.00K
Net Income	-$5.15M	-$4.83M	-$3.46M	-$3.17M
Diluted EPS	-30.40	-10.63	-2.79	-1.89
Diluted Shares	169700	455000	1.24M	1.68M

SNOA Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$3.82M	$3.13M	$5.37M	$2.40M
Receivables	$6.42M	$5.99M	$3.76M	$5.43M
Inventory	$2.86M	$2.72M	$2.92M	$3.65M
Current Assets	$13.80M	$12.55M	$12.65M	$12.10M
Total Assets	$16.23M	$14.74M	$13.69M	$13.96M
Current Liabilities	$3.72M	$3.72M	$4.10M	$4.83M
Total Debt	$849.00K	$608.00K	$305.00K	$842.00K
Total Liabilities	$8.25M	$8.60M	$9.28M	$10.87M
Retained Earnings	-$189.51M	-$194.35M	-$197.81M	-$200.98M
Shareholders' Equity	$7.98M	$6.14M	$4.41M	$3.10M
Working Capital	$10.08M	$8.83M	$8.55M	$7.27M

SNOA Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$6.15M	-$2.40M	-$88.00K	-$3.93M
Capital Expenditure	-$269.00K	-$2.00K	-$80.00K	-$192.00K
Free Cash Flow	-$6.42M	-$2.40M	-$168.00K	-$4.13M
Depreciation & Amortisation	$125.00K	$176.00K	$138.00K	$139.00K
Stock-Based Compensation	$669.00K	$516.00K	$224.00K	$255.00K
Investing Cash Flow	-$258.00K	-$2.00K	-$80.00K	-$192.00K
Financing Cash Flow	$2.49M	$1.68M	$3.03M	$477.00K
Share Repurchases	—	$0.00	-$1.00K	$0.00
Net Change in Cash	-$3.92M	-$724.00K	$2.86M	-$3.65M

SNOA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.75M	$4.01M	$5.60M	$4.35M	$5.56M	$6.41M
Cost of Revenue	$2.23M	$2.55M	$3.48M	$2.70M	$3.38M	$3.83M
Gross Profit	$1.53M	$1.46M	$2.12M	$1.65M	$2.18M	$2.58M
Research & Development	$411.00K	$594.00K	$575.00K	$557.00K	$545.00K	$597.00K
Selling, General & Admin	$1.77M	$1.97M	$1.88M	$1.77M	$1.99M	$2.02M
Operating Expenses	$2.18M	$2.56M	$2.46M	$2.33M	$2.53M	$2.62M
Operating Income	-$656.00K	-$1.09M	-$337.00K	-$678.00K	-$351.00K	-$40.00K
EBITDA	-$625.00K	-$1.06M	-$301.00K	-$644.00K	-$318.00K	-$8.00K
Pretax Income	-$528.00K	-$1.24M	-$731.00K	-$949.00K	-$497.00K	-$330.00K
Income Tax	$248.00K	-$1.00K	-$197.00K	-$130.00K	$84.00K	$0.00
Net Income	-$776.00K	-$1.24M	-$534.00K	-$819.00K	-$581.00K	-$330.00K
Diluted EPS	—	-0.76	-0.32	-0.48	—	-0.09
Diluted Shares	—	1.64M	1.65M	1.71M	—	3.85M

SNOA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.37M	$3.60M	$3.04M	$2.56M	$2.40M	$5.34M
Receivables	$3.76M	$2.60M	$2.70M	$2.38M	$5.43M	$3.18M
Inventory	$2.92M	$3.80M	$3.63M	$3.70M	$3.65M	$3.79M
Current Assets	$12.65M	$13.11M	$12.50M	$12.14M	$12.10M	$16.27M
Total Assets	$13.69M	$14.59M	$13.86M	$13.62M	$13.96M	$18.11M
Current Liabilities	$4.10M	$4.85M	$4.32M	$4.22M	$4.83M	$5.45M
Total Debt	$305.00K	$675.00K	$535.00K	$655.00K	$842.00K	$739.00K
Total Liabilities	$9.28M	$10.54M	$10.07M	$10.19M	$10.87M	$11.51M
Retained Earnings	-$197.81M	-$199.05M	-$199.58M	-$200.40M	-$200.98M	-$201.31M
Shareholders' Equity	$4.41M	$4.06M	$3.79M	$3.43M	$3.10M	$6.59M
Working Capital	$8.55M	$8.26M	$8.18M	$7.93M	$7.27M	$10.82M

SNOA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$95.00K	-$2.02M	-$635.00K	-$764.00K	-$519.00K	-$649.00K
Capital Expenditure	-$47.00K	-$106.00K	-$10.00K	-$47.00K	-$29.00K	-$2.00K
Free Cash Flow	-$142.00K	-$2.12M	-$645.00K	-$811.00K	-$548.00K	-$651.00K
Depreciation & Amortisation	$31.00K	$36.00K	$36.00K	$34.00K	$33.00K	$32.00K
Stock-Based Compensation	$90.00K	$57.00K	$39.00K	$24.00K	$135.00K	$58.00K
Investing Cash Flow	-$47.00K	-$106.00K	-$10.00K	-$47.00K	-$29.00K	-$2.00K
Financing Cash Flow	$242.00K	-$58.00K	-$62.00K	$210.00K	$387.00K	$3.45M
Share Repurchases	$0.00	—	—	—	$0.00	—
Net Change in Cash	$100.00K	-$2.18M	-$707.00K	-$601.00K	-$161.00K	$2.80M

Market Snapshot

About

Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid products for various markets. The company focuses on dermatological and eye care applications, offering antimicrobial solutions that harness the natural power of the human immune system. Sonoma markets products under multiple brands including Microcyn, Celacyn, and DERMAdoctor.